Newborn Acquisition Corp

This is the clearest statement that the extension is UNFUNDED — holders are asked for three more months with nothing added to trust — which is the fact that decides whether staying is worth more than the roughly $10.06 per share on offer. The meeting time also matters: stated in Hong Kong time, it falls on the previous evening in New York, so a redemption or voting deadline computed from a US calendar date can be a day out. The reminder about brokers is the standard signal that turnout, not opposition, is the risk.

The purpose is to reach the announced Nuvve Corporation combination, and the company's own press releases describe this extension as proceeding 'without depositing additional funds in the company's trust account' — so the $575,000 ($0.10 per share) insider deposit the proxy describes, payable against a note convertible into private units at $10.00, belongs to the pre-existing charter mechanic and should not be read as new money for these three months. At about $10.06 the trust has little cushion, and a special resolution is a higher bar than a simple majority.

The record date, the meeting date, the per-share trust figure, the record-date closing price and the share counts are all left as empty brackets, so this document fixes no deadline a holder can act on; only the definitive version will. The $0.10 per share deposit is funded by a note repayable out of a completed combination, so it is a loan against success rather than a gift to the trust. The filing is explicit about the downside: if the amendments fail and insiders do not extend, Newborn may be unable to close the Nuvve deal by 19 Feb 2021 and must wind up and redeem 100% of public shares.

The estimated Closing Exchange Ratio is approximately 0.2081, giving an estimated 8,852,828 PubCo shares to Nuvve's stockholders after the repurchase of 600,000 shares from one of them. The financing beside it is small: a PIPE of 1,425,000 Newborn ordinary shares at $10.00 per share, $14,250,000 in all, with warrants over a further 1,353,750 shares on the same terms as the public warrants — each entitling the holder to buy one-half of one share at $11.50 per whole share — plus a $4,000,000 convertible debenture purchased on November 17, 2020 that converts immediately before closing.

Nearly the whole nine-month loss is non-cash: the sponsor transferred 100,000 shares to a special advisor for $10 of cash and the company expensed $969,990 of fair value, so the reported loss badly overstates cash burn. Equity of exactly $5,000,001 is the net-tangible-asset plug, not a finding. The trust figure is as of September 30, 2020 only. MD&A misprints the comparative period as 'April 12, 2020 (Inception) through September 30, 2019'; inception was April 12, 2019.

Nearly all of the quarter's loss is a non-cash charge for shares the sponsor gave away, not spending by the company - a reader comparing quarterly losses across shells would otherwise treat this as a burn rate. The trust figure is a June 30, 2020 balance and the $10.0534 is a carrying value stated to four decimals, not a redemption price. Cover reconciles: 5,148,985 + 2,311,015 = the 7,460,000 shares stated at August 13, 2020. Nothing was written to a trust, price or status field.

Read carelessly this filing looks like a funded SPAC; it is not. NOTHING of the $57,500,000 was in trust at December 31, 2019, so that figure is not a balance-sheet number and must never be attached to this period. The document also contradicts itself on a date: it says 'On February 19, 2017, the underwriter fully exercised the over-allotment', two years before the April 12, 2019 incorporation and three years before the actual February 19, 2020 exercise it describes elsewhere - carried-forward boilerplate, flagged not resolved. February 19 / August 19, 2021 are charter dates only.

This is the SPAC's formation event. Each unit is one ordinary share, one warrant for half a share at $11.50, and one right to one-tenth of a share on completion of an initial business combination, so the rights dilute at closing regardless of the warrants. Item 3.02 reports the concurrent private placement of 272,500 units at $10.00 to sponsor NeoGenesis Holding Co. Ltd for $2,725,000, those warrants non-redeemable and cashless-exercisable. The report states no business-combination deadline; it says an audited balance sheet as of February 19 will be filed within four business days.

Three defaults fail here at once. The warrant is for half a share, not a whole one. The call trigger is $16.50, which the document names the Force-Call Provision, for 20 of 30 trading days and only while a current registration statement is in effect. And deferred underwriting is $0.25 per unit against the usual $0.35, so more of the trust belongs to holders. The provisions protecting the trust can be amended by holders of only 50% of the shares sold in the offering, but every public shareholder - for or against - is then granted the right to convert.

What changed: Newborn Acquisition Corp. issued its definitive proxy statement/prospectus, dated February 16, 2021 and first mailed on or about February 17, 2021, fixing the extraordinary general meeting for March 17, 2021 at 8:00 a.m. Hong Kong Time — 7:00 p.m. Eastern Time on March 16, 2021 — at Room 801, Building C, SOHO Square in Shanghai, with shareholders encouraged to attend by teleconference. The two-step combination with Nuvve Corporation under the merger agreement dated November 11, 2020 is otherwise unchanged. Why it matters: The estimated Closing Exchange Ratio has been revised upward from the preliminary version to approximately 0.2124, giving an estimated 9,068,419 PubCo shares to Nuvve's stockholders after the repurchase of 600,000 shares from one of them, with 1,301,715 shares reserved for the Nuvve options PubCo assumes. This version also discloses that an estimated 912,460 of the shares issued to Nuvve's stockholders will be held in escrow to satisfy indemnification obligations. The PIPE remains 1,425,000 shares at $10.00 per share, $14,250,000, with warrants over a further 1,353,750 shares.

What changed: Form 8-K filed as additional proxy material carrying Newborn's press release of 10 Feb 2021 urging shareholders to vote for the extension proposals. It restates the mechanics in bullet form: record-date holders as of the close of business on 15 Jan 2021 keep the vote 'even if you no longer own those shares'; 'the trust amendment proposal requires 50% of the outstanding shares held by public shareholders to vote in favor (management shares don't count towards approval of this proposal)'; and 'all votes must be received by February 17, 2021'. Why it matters: It fixes a deadline that is NOT the meeting date and is easy to miss — votes had to be in by 17 Feb 2021 for a meeting held on 18 Feb 2021 Hong Kong time — and it states in terms that founder shares are excluded from the trust-amendment denominator, so the sponsor cannot carry this proposal alone. Taken with the 8 Feb 2021 postponement, the sequence documents a SPAC struggling to reach a public-shareholder threshold nine days before its charter deadline, with no sponsor deposit offered to improve the terms.